Agios
AGIO
Agios (AGIO) news
Recent news
Agios Pharmaceuticals shares down 5.8% as it discontinues sickle cell disease drug development
AInvest Wire · Jul 21, 2026ImportantAgios shares drop 14% after Phase 2 trial update
AInvest Wire · Jul 21, 2026ImportantAgios Pharmaceuticals shares down 12.6% premarket as it discontinues sickle cell disease drug development
AInvest Wire · Jul 21, 2026Agios Phase 2 did not establish a differentiated profile
AInvest Wire · Jul 21, 2026Agios Pharmaceuticals shares rise 12.4% after US FDA grants priority review to sickle cell disease drug
Agios Pharmaceuticals received priority review from the U.S. FDA for its new drug application (SNDA) for mitapivat, targeting sickle cell disease, with a PDUFA goal date set for November 1, 2026, and its shares rose 12.4% following the announcement, per reports from multiple financial news sources.
AInvest Wire · Jul 7, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.